The ROSECAN project
"Joint initiative Romania - Serbia against cancer in the cross-border region: improving the diagnosis and treatment of malignant tumors" - ROSECAN
Duration of the project
42 months (+10 months extension)
Požarevac General Hospital
Ministry of Health – Republic of Serbia
OncoGen-Pius Brânzeu Emergency County Clinical Hospital, Timișoara
Reșita Emergency County Hospital
The Center for Gene and Cell Therapies in Cancer Treatment - OncoGen implements the strategic project "Romania-Serbia joint initiative against cancer in the cross-border region: improving the diagnosis and treatment of malignant tumors - ROSECAN", financed by the Interreg-IPA Program CBC Romania - Serbia.
The objective of the ROSECAN project is to develop oncology in the region through a modern and efficient infrastructure, with the aim of ensuring patients' access to high-quality services for the diagnosis and treatment of cancer.
The project is coordinated by the Požarevac General Hospital, and the partners are the Ministry of Health of the Republic of Serbia, the "Pius Brînzeu" County Emergency Clinical Hospital - OncoGen Timișoara and the Reșița Emergency Hospital.
The project has a duration of 42 months and a budget of €12 million, of which €3 million is allocated to the OncoGen Center, the institution's contribution representing 2% of the funding amount.
More information about the project is available at: www.rosecan.rs/home.html
Through this project, the OncoGen Centre purchased medical and IT equipment worth 2.3 million and is developing a specialized software platform that will be available to doctors in Serbia and Romania and that will allow the rapid exchange of information between them in order to establish the diagnosis and treatment of oncological patients.
At OncoGen, the next-generation sequencing (NGS) technology will be used for screening, prevention and therapeutic guidance in cancer.
A primary goal is to develop a molecular diagnosis-based strategy for cancer patients, which will help oncologists make improved and more effective therapeutic decisions for patients with solid tumors. Ultimately, patients will benefit from precision molecular diagnostics and access to ongoing clinical trials.